Alain Ravaud

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2134001/publications.pdf

Version: 2024-02-01

215 papers	30,684 citations	24978 57 h-index	4535 171 g-index
236 all docs	236 docs citations	236 times ranked	24426 citing authors

#	Article	IF	Citations
1	Development of an evidence-based reference framework for care coordination with a focus on the micro level of integrated care: A mixed method design study combining scoping review of reviews and nominal group technique. Health Policy, 2022, 126, 245-261.	1.4	2
2	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022, 82, 212-222.	0.9	56
3	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	0.9	64
4	Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncology, 2021, 17, 403-409.	1.1	1
5	Estimand framework: Are we asking the right questions? A case study in the solid tumor setting. Pharmaceutical Statistics, 2021, 20, 324-334.	0.7	8
6	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154
7	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. European Urology Oncology, 2021, 4, 274-281.	2.6	7
8	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Communications Biology, 2021, 4, 166.	2.0	19
9	A Step Ahead in Metastatic Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1360-1361.	13.9	5
10	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nature Medicine, 2021, 27, 793-801.	15.2	56
11	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2021, 39, 6020-6020.	0.8	4
12	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	0.9	20
13	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, 2021, 4, 456-463.	2.6	18
14	Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. Immunotherapy, 2021, 13, 741-744.	1.0	1
15	Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives. Cancer Treatment Reviews, 2021, 97, 102207.	3.4	35
16	VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. Journal of Geriatric Oncology, 2021, 12, 759-764.	0.5	5
17	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. European Urology, 2021, 80, 7-11.	0.9	60
18	New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?. European Urology, 2021, 80, 269-274.	0.9	7

#	Article	IF	Citations
19	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta OncolÃ³gica, 2021, 60, 1597-1603.	0.8	13
20	Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?. European Urology, 2021, 80, 417-424.	0.9	67
21	Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression. Molecular Cancer, 2021, 20, 136.	7.9	17
22	Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. European Journal of Cancer, 2021, 157, 474-484.	1.3	45
23	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review. European Journal of Cancer, 2021, 158, 47-62.	1.3	32
24	Long-term prognosis of septic shock in cancer patients. Supportive Care in Cancer, 2020, 28, 1325-1333.	1.0	14
25	Clinical outcome after progressing to frontline and second-line Antiâ€“PD-1/PD-L1 in advanced urothelial cancer. European Urology, 2020, 77, 269-276.	0.9	45
26	The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus study. European Journal of Surgical Oncology, 2020, 46, 470-475.	0.5	1
27	Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. , 2020, 8, e001246.		49
28	Management of Immune Checkpoint Inhibitor Toxicities . Cancer Management and Research, 2020, Volume 12, 9139-9158.	0.9	18
29	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in firstâ€line metastatic renal carcinoma (SUNRISES study). BJU International, 2020, 126, 559-567.	1.3	5
30	Current management and future perspectives of penile cancer: An updated review. Cancer Treatment Reviews, 2020, 90, 102087.	3.4	16
31	Safety of sunitinib in patients with renal cell carcinoma following nephrectomy. Expert Opinion on Drug Safety, 2020, 19, 799-806.	1.0	2
32	Adaptation of multidisciplinary meetingÂdecisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital. European Journal of Cancer, 2020, 135, 98-100.	1.3	1
33	Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. Clinical Cancer Research, 2020, 26, 4863-4868.	3.2	14
34	Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 86, 97-108.	1.1	8
35	Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients. Frontiers in Surgery, 2020, 7, 26.	0.6	2
36	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. European Journal of Cancer, 2020, 129, 107-116.	1.3	35

#	Article	IF	Citations
37	The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. Lancet Oncology, The, 2020, 21, 619-621.	5.1	155
38	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. British Journal of Clinical Pharmacology, 2020, 86, 1807-1818.	1.1	14
39	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. Pharmacology Research and Perspectives, 2020, 8, e00613.	1.1	6
40	Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. Bulletin Du Cancer, 2020, 107, eS1-eS7.	0.6	4
41	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-Î² and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. , 2020, 8, e000664.		48
42	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer, 2020, 136, 76-83.	1.3	19
43	Prognostic factors for cancer patient admitted to a medical intensive care unit. Acta OncolÃ³gica, 2020, 59, 458-461.	0.8	3
44	Atezolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 679-686.	1.4	0
45	Patientâ€reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	1.3	19
46	Which place for avelumab in the management of urothelial carcinoma?. Expert Opinion on Biological Therapy, 2019, 19, 863-870.	1.4	4
47	Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. , 2019, 7, 275.		48
48	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine, 2019, 25, 1706-1714.	15.2	407
49	Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy. JAMA Oncology, 2019, 5, 623.	3.4	25
50	The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report. Oral Oncology, 2019, 94, 125-127.	0.8	2
51	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e721-e723.	0.9	7
52	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
53	Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression. Clinical Genitourinary Cancer, 2019, 17, 169-176.e1.	0.9	2
54	Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. Clinical Pharmacokinetics, 2019, 58, 1165-1174.	1.6	19

#	Article	IF	Citations
55	Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience. BMC Cancer, 2019, 19, 1182.	1.1	22
56	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research, 2019, 25, 1165-1173.	3.2	23
57	Dramatic response under combination of immune-oncology in head & neck cancer included in the Condor study: A case report. Oral Oncology, 2019, 89, 150-152.	0.8	0
58	Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. Clinical Colorectal Cancer, 2019, 18, e150-e162.	1.0	3
59	Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clinical Cancer Research, 2018, 24, 1554-1561.	3.2	34
60	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2018, 391, 748-757.	6.3	1,142
61	Alterations in comprehensive geriatric assessment decrease survival of elderly patients with cancer. European Journal of Cancer, 2018, 90, 10-18.	1.3	30
62	Progression beyond nivolumab: Stop or repeat? Dramatic responses with salvage chemotherapy. Oral Oncology, 2018, 81, 116-118.	0.8	17
63	Treatment of spinal metastases in renal cell carcinoma: A critical review. Critical Reviews in Oncology/Hematology, 2018, 125, 19-29.	2.0	12
64	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
65	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naÃ¯ve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. European Urology, 2018, 73, 696-703.	0.9	45
66	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. European Urology, 2018, 73, 62-68.	0.9	164
67	Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncology, The, 2018, 19, 51-64.	5.1	491
68	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancerâ€"clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Annals of the Rheumatic Diseases, 2018, 77, 393-398.	0.5	230
69	Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizzoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62â€"8. European Urology, 2018, 73, e73.	0.9	1
70	Adjuvant therapy after nephrectomy for renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 33-36.	0.7	1
71	Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus. Oral Oncology, 2018, 87, 207-209.	0.8	3
72	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. Clinical Cancer Research, 2018, 24, 4407-4415.	3.2	50

#	Article	IF	Citations
73	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. Clinical Cancer Research, 2018, 24, 5534-5542.	3.2	15
74	Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. Theranostics, 2018, 8, 2447-2458.	4.6	16
75	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 417-427.	13.9	684
76	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	15.2	900
77	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. Journal of Clinical Oncology, 2018, 36, 4506-4506.	0.8	69
78	Neutrophil-to-lymphocyte ratio as a potential prognostic factor of disease-free survival in high-risk renal cell carcinoma: Analysis of the S-TRAC trial.. Journal of Clinical Oncology, 2018, 36, 4562-4562.	0.8	1
79	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinomaâ€"Results of a phase III noninferiority trial.. Journal of Clinical Oncology, 2018, 36, LBA3-LBA3.	0.8	10
80	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology, 2018, 36, 578-578.	0.8	164
81	Disease-free survival in patients at highest risk of recurrent renal cell carcinoma in S-TRAC.. Journal of Clinical Oncology, 2018, 36, 4565-4565.	0.8	0
82	Prognostic factors in critically ill patients with solid cancer admitted to medical intensive care unit.. Journal of Clinical Oncology, 2018, 36, e18745-e18745.	0.8	0
83	Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas. Cancer Research, 2017, 77, 1212-1226.	0.4	74
84	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	0.9	209
85	Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. Oncology, 2017, 92, 243-254.	0.9	4
86	Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib. Future Oncology, 2017, 13, 1219-1221.	1.1	1
87	A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France. Supportive Care in Cancer, 2017, 25, 2055-2062.	1.0	6
88	Realâ€life patterns of use, safety and effectiveness of sunitinib in firstâ€line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1561-1569.	0.9	18
89	Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2017, 15, e885-e887.	0.9	3
90	Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy. Targeted Oncology, 2017, 12, 487-494.	1.7	25

#	Article	IF	Citations
91	A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. European Journal of Cancer, 2017, 76, 110-117.	1.3	89
92	Sorafenib dose escalation in treatmentâ€naÃ¯ve patients with metastatic renal cell carcinoma: a nonâ€randomised, openâ€label, Phase 2b study. BJU International, 2017, 119, 846-853.	1.3	3
93	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European Journal of Cancer, 2017, 85, 39-48.	1.3	2
94	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e7-603.e14.	0.8	0
95	Immune checkpoint inhibitors and elderly people: AÂreview. European Journal of Cancer, 2017, 82, 155-166.	1.3	148
96	Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment. Oral Oncology, 2017, 64, e1-e3.	0.8	13
97	Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	0.8	538
98	Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers. , 2017, , .		1
99	Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2016, 14, e525-e527.	0.9	1
100	Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. Journal of Geriatric Oncology, 2016, 7, 187-194.	0.5	14
101	m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature. Oral Oncology, 2016, 62, e1-e2.	0.8	2
102	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 2016, 375, 2246-2254.	13.9	640
103	Targeted therapy and elderly people: A review. European Journal of Cancer, 2016, 69, 199-215.	1.3	34
104	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clinical Genitourinary Cancer, 2016, 14, 406-414.	0.9	8
105	Are we ready for day-case partial nephrectomy?. World Journal of Urology, 2016, 34, 883-887.	1.2	14
106	Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 1660-1668.	0.8	99
107	Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. Targeted Oncology, 2016, 11, 83-92.	1.7	3
108	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. Annals of Oncology, 2015, 26, 2392-2398.	0.6	25

#	Article	IF	Citations
109	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncology, The, 2015, 16, 787-794.	5.1	206
110	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. BJU International, 2015, 115, 65-73.	1.3	9
111	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 339.e9-339.e15.	0.8	57
112	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model. European Urology, 2015, 68, 196-204.	0.9	102
113	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	13.9	4,889
114	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. Journal of Clinical Oncology, 2015, 33, 3431-3438.	0.8	49
115	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. , 2015, , 365-384.		0
116	Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opinion on Drug Safety, 2014, 13, 361-372.	1.0	30
117	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta OncolÃ³gica, 2014, 53, 1413-1422.	0.8	30
118	How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. British Journal of Clinical Pharmacology, 2014, 77, 498-508.	1.1	8
119	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer. Clinical Cancer Research, 2014, 20, 3012-3022.	3.2	48
120	Protein kinase inhibitors in renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2014, 15, 337-351.	0.9	8
121	Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology. European Journal of Cancer, 2014, 50, 486-495.	1.3	66
122	Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Targeted Oncology, 2014, 9, 311-319.	1.7	21
123	A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases. Clinical Genitourinary Cancer, 2014, 12, 50-54.	0.9	66
124	Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3Âyears, a case report and review of the literature. Targeted Oncology, 2014, 9, 81-84.	1.7	3
125	Pulmonary Aspergilloma: An Unexpected Complication of Radiofrequency Ablation in the Management of Targeted Therapy for a Patient With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e115-e116.	0.9	1
126	Patientsâ€™ self-assessment versus investigatorsâ€™ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). European Journal of Cancer, 2014, 50, 953-962.	1.3	63

#	Article	IF	Citations
127	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 149-158.	5.1	586
128	Emerging antiangiogenics for renal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 495-511.	1.0	15
129	Are Tyrosine Kinase Inhibitors Still Active in Patients With Metastatic Renal Cell Carcinoma Previously Treated With a Tyrosine Kinase Inhibitor and Everolimus? Experience of 36 Patients Treated in France in the RECORD-1 Trial. Clinical Genitourinary Cancer, 2013, 11, 128-133.	0.9	14
130	Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications. Cancer Treatment Reviews, 2013, 39, 784-792.	3.4	25
131	Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers. Cancer Treatment Reviews, 2013, 39, 230-240.	3.4	22
132	What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?. Cancer Treatment Reviews, 2013, 39, 366-374.	3.4	29
133	Combination Therapy in Metastatic Renal Cell Cancer. Seminars in Oncology, 2013, 40, 472-481.	0.8	21
134	The experimental renal cell carcinoma model in the chick embryo. Angiogenesis, 2013, 16, 181-194.	3.7	46
135	The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World Journal of Urology, 2013, 31, 1383-1388.	1.2	9
136	Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy. Journal of Clinical Oncology, 2013, 31, 3877-3882.	0.8	201
137	Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10594.	0.6	75
138	Optimal management of renal cell carcinoma in the elderly: a review. Clinical Interventions in Aging, 2013, 8, 433.	1.3	35
139	Real-life patterns of use and effectiveness of sunitinib in patients with metastatic renal cell carcinoma: The SANTORIN study.. Journal of Clinical Oncology, 2013, 31, 400-400.	0.8	5
140	Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2012, 4, 253-265.	0.9	30
141	Lapatinib and renal cell carcinoma. Expert Opinion on Investigational Drugs, 2012, 21, 1727-1732.	1.9	3
142	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treatment Reviews, 2012, 38, 127-132.	3.4	9
143	A phase III trial of docetaxelâ€“estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial. European Journal of Cancer, 2012, 48, 209-217.	1.3	47
144	Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treatment Reviews, 2012, 38, 996-1003.	3.4	42

#	Article	IF	Citations
145	Quitter enfin des mauvais rÃ©sultats de la chimiothÃ©rapie dans le cancer du pancrÃ©as mÃ©tastatique grÃ¢ce Ã un groupe coopÃ©ratif franÃ§ais. Bulletin Du Cancer, 2012, 99, 405.	0.6	0
146	AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney. Cancer, 2012, 118, 6152-6161.	2.0	97
147	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. European Urology, 2012, 61, 826-833.	0.9	59
148	Editorial Comment to Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. International Journal of Urology, 2012, 19, 805-805.	0.5	2
149	Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year. Current Urology Reports, 2012, 13, 16-23.	1.0	17
150	Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. Journal of Clinical Oncology, 2012, 30, 1829-1834.	0.8	366
151	Safety and efficacy of AMG 386 in combination with sunitinib in patients with metastatic renal cell carcinoma (mRCC) in an open-label multicenter phase II study.. Journal of Clinical Oncology, 2012, 30, 4606-4606.	0.8	5
152	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. , 2012, , 265-283.		0
153	Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?. Translational Andrology and Urology, 2012, 1, 197-8.	0.6	0
154	Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. Acta OncolÃ³gica, 2011, 50, 1135-1136.	0.8	7
155	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer, 2011, 47, 1287-1298.	1.3	133
156	Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 4-11.	0.8	24
157	Exposureâ€“response relationships in patients with metastatic renal cell carcinoma receiving sunitinib. Anti-Cancer Drugs, 2011, 22, 377-383.	0.7	16
158	Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferonâ€±2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU International, 2011, 107, 214-219.	1.3	43
159	Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01). European Urology, 2011, 60, 1251-1257.	0.9	29
160	Lung Tumors Treated With Percutaneous Radiofrequency Ablation: Computed Tomography Imaging Follow-Up. CardioVascular and Interventional Radiology, 2011, 34, 989-997.	0.9	73
161	Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies. Oncologist, 2011, 16, 32-44.	1.9	78
162	Bladder cancer in patients after organ transplantation. Current Opinion in Urology, 2010, 20, 432-436.	0.9	13

#	Article	IF	Citations
163	Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer, 2010, 116, 4256-4265.	2.0	1,039
164	Efficacy of Sunitinib in Advanced Medullary Thyroid Carcinoma: Intermediate Results of Phase II THYSU. Oncologist, 2010, 15, 212-213.	1.9	55
165	Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival. Journal of Clinical Oncology, 2010, 28, 2144-2150.	0.8	767
166	Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 396-403.	2.5	202
167	Amplification of epidermal growth factor receptor gene in renal cell carcinoma. European Journal of Cancer, 2010, 46, 859-862.	1.3	11
168	Therapeutic Management of De Novo Urological Malignancy in Renal Transplant Recipients: The Experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology, 2010, 75, 126-132.	0.5	62
169	The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 473-479.	0.8	100
170	Metronomic chemotherapy for renal cancer in the landscape of targeted therapy. Lancet Oncology, The, 2010, 11, 307-308.	5.1	2
171	Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice. Cancer Investigation, 2010, 28, 856-864.	0.6	35
172	Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Archivos Espanoles De Urologia, 2010, 63, 773-87.	0.1	5
173	Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma. European Urology, 2009, 55, 1477-1480.	0.9	60
174	Laparoscopic Radical Prostatectomy in Renal Transplant Recipients. Urology, 2009, 74, 683-687.	0.5	33
175	Molecular Pathways in Metastatic Renal Cell Carcinoma: The Evolving Role of Mammalian Target of Rapamycin Inhibitors. European Urology Supplements, 2009, 8, 793-798.	0.1	5
176	Current and Future Treatment Options for Metastatic Renal Cell Carcinoma. European Urology Supplements, 2009, 8, 799-808.	0.1	4
177	Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma. European Urology Supplements, 2009, 8, 815-819.	0.1	2
178	Update on the Medical Treatment of Metastatic Renal Cell Carcinoma. European Urology, 2008, 54, 315-325.	0.9	54
179	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, The, 2008, 372, 449-456.	6.3	2,848
180	Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology, 2008, 26, 2285-2291.	0.8	90

#	Article	IF	Citations
181	Randomized Study of Intravenous versus Subcutaneous Interleukin-2, and IFNÎ± in Patients with Good Prognosis Metastatic Renal Cancer. Clinical Cancer Research, 2008, 14, 5907-5912.	3.2	26
182	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. Journal of Clinical Oncology, 2008, 26, 127-131.	0.8	373
183	Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways. Current Opinion in Urology, 2008, 18, 524-532.	0.9	38
184	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, The, 2007, 370, 2103-2111.	6.3	2,140
185	Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse-event management and key considerations. European Journal of Cancer, Supplement, 2007, 5, 1-3.	2.2	1
186	Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib. European Journal of Cancer, Supplement, 2007, 5, 4-11.	2.2	2
187	Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. European Journal of Cancer, Supplement, 2007, 5, 12-19.	2.2	26
188	Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma. European Journal of Cancer, Supplement, 2007, 5, 20-27.	2.2	4
189	Prognostic Factors of Metastatic Renal Cell Carcinoma After Failure of Immunotherapy: New Paradigm From a Large Phase III Trial With Shark Cartilage Extract AE 941. Journal of Urology, 2007, 178, 1901-1905.	0.2	57
190	Medroxyprogesterone, interferon alfaâ€2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer, 2007, 110, 2448-2457.	2.0	186
191	Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 137, 490-490.	1.2	12
192	Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma. Targeted Oncology, 2007, 2, 99-105.	1.7	6
193	MÃ©tastases vertÃ©brales des cancers du rein. , 2007, , 155-163.		0
194	Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation. Radiology, 2006, 240, 587-596.	3.6	347
195	Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe FranÃ§ais dâ€™ImmunothÃ©rapie. World Journal of Urology, 2005, 23, 161-165.	1.2	46
196	Current Strategy in the Treatment of Metastatic Renal Cell Carcinoma. Current Cancer Therapy Reviews, 2005, 1, 127-137.	0.2	1
197	Interferon alpha for the treatment of advanced renal cancer. Expert Opinion on Biological Therapy, 2005, 5, 749-762.	1.4	12
198	Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6â€"From the Groupe FranÃ§ais d'ImmunothÃ©rapie. Journal of Clinical Oncology, 2004, 22, 2371-2378.	0.8	158

#	Article	IF	Citations
199	Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain, Behavior, and Immunity, 2004, 18, 205-213.	2.0	217
200	Symptomatic Neurological Epidural Metastasis with Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma. Tumori, 2002, 88, 338-340.	0.6	6
201	Subcutaneous interleukin-2 and interferon Î± in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon Î±. Cancer, 2002, 95, 2324-2330.	2.0	21
202	Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-Î± Treatments in Cancer Patients. Psychosomatic Medicine, 2001, 63, 376-386.	1.3	132
203	Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology, 2001, 26, 797-808.	1.3	182
204	Early Depressive Symptoms in Cancer Patients Receiving Interleukin 2 and/or Interferon Alfa-2b Therapy. Journal of Clinical Oncology, 2000, 18, 2143-2151.	0.8	270
205	Taxane-induced glaucoma. Lancet, The, 2000, 355, 577.	6.3	1
206	Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?. Journal of Clinical Oncology, 1999, 17, 2039-2039.	0.8	95
207	Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State. New England Journal of Medicine, 1999, 340, 1370-1370.	13.9	158
208	Present achievements in the medical treatment of metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology, 1999, 31, 77-88.	2.0	14
209	Taxane-induced glaucoma. Lancet, The, 1999, 354, 1181-1182.	6.3	26
210	Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1272-1278.	13.9	914
211	Phase II Study of Interferon-?? and All-Trans Retinoic Acid in Metastatic Renal Cell Carcinoma. Journal of Immunotherapy, 1998, 21, 62-64.	1.2	13
212	A survey in general practice about undergraduate cancer education: Results from gironde (france). Journal of Cancer Education, 1991, 6, 153-157.	0.6	11
213	Cancer chemotherapy in the elderly: a series of 51 patients aged>70 years. Cancer Chemotherapy and Pharmacology, 1991, 29, 159-163.	1.1	18
214	Metastatic Renal Cell Carcinoma. , 0, , 387-394.		0
215	An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives. Therapeutics and Clinical Risk Management, 0, Volume 18, 619-632.	0.9	5